Trimble introduced a Hardware-as-a-Service option for its Transportation fleet mobility solutions. This new service consists of four bundles, enabling fleets to purchase Trimble hardware and software solutions and upgrade without upfront capital investment. ...
American Airlines looks to secure $3.5 billion in new financing and United Airlines may receive a $5 billion debt offering from a group of banks led by Goldman Sachs. Yahoo Finance’s On The Move panel addresses the state of U.S. airlines....
Stocks were mixed Monday as market participants weighed prospects that the virus-stricken economy would rebound quickly against fears over an extended rise in new cases over the weekend....
Yahoo Finance’s Brian Sozzi and Alexis Christoforous discuss the reopening of amusement parks across the world, and cruise industry outlook with Wedbush Securities Managing Director James Hardiman....
Inphi bounced from its 10-week line. Arguably the data center chip leader right now, Inphi was one of the first stocks to break out after the market crash....
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets.It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week high of $6.54 and a 52-week low of $1.75.Latest Ratings for FPRX DateFirmActionFromTo Jun 2020WedbushUpgradesNeutralOutperform Feb 2020JP MorganDowngradesNeutralUnderweight Feb 2020WedbushDowngradesOutperformNeutral View More Analyst...
